The Patent Finder

Terms ending in 2035

Adimab, LLC

Every in-force patent on Adimab, LLC's record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 11,390,964Polyclonal Mixtures of Antibodies, and Methods of Making and Using Them
In force
 · High confidence
Adimab, LLCIn forceHigh confidence
US 12,258,679Polyclonal Mixtures of Antibodies, and Methods of Making and Using Them
In force
 · High confidence
Adimab, LLCIn forceHigh confidence
US 12,733,934Adapter, Extension, and Connector Assemblies for Surgical Devices
In force
 · High confidence
Adimab, LLCIn forceHigh confidence
US 10,882,920Antibodies Against BACE1 and Use Thereof for Neural Disease Immunotherapy
In force
 · High confidence
Adimab LLCIn forceHigh confidence
US 11,008,403Anti-Transferrin Receptor / ANTI-BACE1 Multispecific Antibodies and Methods of Use
In force
 · High confidence
Adimab LLCIn forceHigh confidence
US 12,181,480Polyspecificity Reagents, Methods for Their Preparation and Use
In force
 · Medium confidence
Adimab, LLCIn forceMedium confidence
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited